Re: Not adding up!

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KayakerBC

Rank: Treasurer [?]

Points: 1691 [?]

Votes: 23 Score: 2.6 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Not adding up!

in response to

Re: Not adding up!

fuzzyjr

posted on Nov 15, 2021 01:46PM

What RVX hopes happens in the Covid trial has no relevance to negotiations for ZEN-3694 and the different diseases Zenith is demonstrating safety and efficacy for. Does anybody really think that because RVX hopes for a good Covid trial, Newsoara would pay more for a license for Zenith's ZEN-3694?

Anyhow, I don't see a problem with today's news. No one even knows what the milesone and royalty payments will be but are critical.

3 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply